| Autor: |
Pine PR; Rigel Pharmaceuticals, Inc., 1180 Veterans Blvd., San Francisco, CA 94080, USA., Chang B, Schoettler N, Banquerigo ML, Wang S, Lau A, Zhao F, Grossbard EB, Payan DG, Brahn E |
| Jazyk: |
angličtina |
| Zdroj: |
Clinical immunology (Orlando, Fla.) [Clin Immunol] 2007 Sep; Vol. 124 (3), pp. 244-57. Date of Electronic Publication: 2007 May 29. |
| DOI: |
10.1016/j.clim.2007.03.543 |
| Abstrakt: |
Spleen tyrosine kinase (Syk), a key mediator of immunoreceptor signaling in inflammatory cells, is essential for immune complex-mediated signal transduction initiated by activated receptors for immunoglobulin G. In collagen-induced arthritis, R788/R406, a novel and potent small molecule Syk inhibitor suppressed clinical arthritis, bone erosions, pannus formation, and synovitis. Serum anti-collagen type II antibody levels were unaltered, while the half-life of exogenous antibody was extended when co-administered with R406. Expression of the targeted kinase (Syk) in synovial tissue correlated with the joint level of inflammatory cell infiltrates and was virtually undetectable in treated rats. Syk inhibition suppressed synovial cytokines and cartilage oligomeric matrix protein (COMP) in serum, suggesting a sensitive and reliable biomarker for R406 activity. These results highlight the role of activating Fcgamma receptors in inflammatory synovitis and suggest that interruption of the signaling cascade with a novel Syk inhibitor may be a useful addition to immunosuppressive disease-modifying anti-rheumatic drugs currently used in the treatment of human autoimmune diseases such as rheumatoid arthritis. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect